Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.

Ali F AltebainawiLulwa A AlfarajAmjad A AlharbiFadwa F AlkhuraisiThamir M Alshammari

Published in: Therapeutic advances in drug safety (2023)

Significant signals of rhabdomyolysis were associated with PPIs. However, its signals were higher in non-statin-included reports than in statin-included reports.

Keyphrases

adverse drug
acute kidney injury
cardiovascular disease
coronary artery disease
electronic health record
public health
emergency department
low density lipoprotein
drug induced
type diabetes